StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

Equities research analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays lowered their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Stock Performance

Shares of Cellectis stock opened at $1.82 on Tuesday. The business has a fifty day simple moving average of $1.84 and a two-hundred day simple moving average of $2.02. The firm has a market capitalization of $101.16 million, a P/E ratio of -1.40 and a beta of 3.09. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 12 month low of $1.41 and a 12 month high of $3.38.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period last year, the firm posted ($0.31) earnings per share. On average, equities analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Large investors have recently made changes to their positions in the company. First Affirmative Financial Network purchased a new stake in Cellectis in the 3rd quarter worth about $45,000. Long Focus Capital Management LLC grew its holdings in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. XTX Topco Ltd bought a new position in Cellectis in the second quarter worth approximately $29,000. Finally, Principal Financial Group Inc. boosted its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares in the last quarter. 63.90% of the stock is owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.